United States Patent 5,663,159: Adefovir Dipivoxil Claim Scope, Expiration, and Patent Landscape

United States Patent No. 5,663,159 covers phosphonate antiviral prodrugs, including adefovir dipivoxil, the active pharmaceutical ingredient in Hepsera. The patent claims broad esterified phosphonate structures, narrower adenine compounds, pharmaceutical compositions, and an oral treatment method for HSV-2, HCMV, or HIV. The patent issued on September 2, 1997 and reached its standard 20-year term in November 2014, subject to the patent’s applicable priority and term calculations.[1]

The patent is no longer an enforceable barrier to generic entry. Adefovir dipivoxil is a small molecule, so biosimilar regulation is not relevant. The principal historical value of the patent was its protection of orally bioavailable ester prodrugs of 9-(2-phosphonylmethoxy)ethyladenine, particularly the bis-pivaloyloxymethyl ester known as adefovir dipivoxil.

What does US Patent 5,663,159 cover?

US 5,663,159 covers antiviral phosphonate derivatives in which one or both phosphonic acid groups are converted into physiologically hydrolyzable ester groups. The central technical concept is a prodrug design that improves oral administration of a polar phosphonate antiviral.

The patent’s claim architecture is:

Claim group	Subject matter	Commercial relevance
Claims 1-2	Broad Formula I, V, and III antiviral compounds or intermediates	Covers families of esterified phosphonate nucleoside analogues
Claims 3-8	Structural limitations involving X, B, and R4	Narrows the chemical genus
Claims 9-12	Specific adenine diesters	Claim 9 directly identifies adefovir dipivoxil
Claim 13	Pharmaceutical composition	Covers a formulation containing a claim 1 compound
Claims 14-17	Narrower Formula III compounds and monoesters	Includes mono-pivaloyloxymethyl adefovir
Claim 18	Oral treatment method for HSV-2, HCMV, or HIV	Protects a specified therapeutic use of adefovir dipivoxil

The patent is primarily a prodrug and composition patent. It is not limited to a single salt, tablet, dosage strength, or manufacturing process.

What chemical structures are protected by the patent?

The independent claims define a phosphonate antiviral framework bearing a purine base and one or more esterified phosphonate substituents.

Nucleobase limitation

The variable B is selected from:

Adenyl, identified as A
Guanyl, identified as G
2,6-diaminopurinyl, identified as DAP

This limitation excludes arbitrary nucleobases. It creates a defined purine-focused genus centered on adenine, guanine, and diaminopurine analogues.

X substitution

X may be:

Hydrogen
Methyl
Hydroxymethyl

The hydrogen embodiment is the most commercially significant because it corresponds to the adefovir core.

Ester promoiety

R4 is a physiologically hydrolyzable group selected from:

CH2OC(O)R5
CH(R5)OC(O)R5

The claim permits R, S, or racemic stereochemistry where the substituted form creates a stereocenter.

R5 may be:

C1-C20 alkyl
Aryl
Aryl-alkyl

The group may be unsubstituted or substituted with hydroxy or halogen.

This language creates substantial breadth around the ester side chain. The patent is not restricted to pivaloyloxymethyl groups. Propionyl, isobutyryl, benzoyl, and other acyl substituents fall within the expressly identified or structurally related scope when the remaining limitations are met.

What patent claims cover adefovir dipivoxil?

Claim 9 expressly covers:

9-(2-phosphonylmethoxy)ethyladenine di(pivaloyloxymethyl)ester.

That compound is adefovir dipivoxil, also called bis-POM-PMEA. Its structure contains:

An adenine purine base.
A 2-phosphonylmethoxyethyl side chain attached at the 9-position.
Two phosphonate ester groups.
Two pivaloyloxymethyl promoieties.

Claim 9 is narrower than claim 1 but commercially stronger because it identifies the principal marketed compound with chemical specificity.

Claim 8 also reaches the adenine, X = H, diester subgenus in which R4 is CH2OC(O)R5. Claim 3 narrows R5 to C1-C20 alkyl. Together, these claims create multiple overlapping routes to the adefovir dipivoxil embodiment.

How broad are the claims to monoester and diester compounds?

The patent protects both monoester and diester forms.

Diester claims

Claims 1 and 9 are directed to structures in which the relevant phosphonate substituents are esterified. Claim 9 identifies the di-pivaloyloxymethyl compound specifically.

Diester protection is commercially important because adefovir dipivoxil is the marketed oral prodrug. The ester groups reduce the phosphonate’s ionization and improve absorption compared with unesterified adefovir, also known as PMEA.

Monoester claims

Claim 2 and claims 14-17 cover Formula III compounds in which one relevant group remains hydroxylated while another is esterified. Claim 17 specifically covers:

9-(2-phosphonylmethoxy)ethyladenine mono(pivaloyloxymethyl)ester.

The monoester claims broaden the estate beyond the commercial diester. They may capture intermediates, active metabolites, or alternative prodrug forms depending on the precise structure and claim interpretation.

What does claim 18 protect?

Claim 18 covers a method of treating HSV-2, HCMV, or HIV in a mammal by orally administering adefovir dipivoxil at an antiviral, nontoxic dose for a sufficient treatment period.

The claim requires:

The specified compound: adefovir dipivoxil.
Oral administration.
A mammalian patient.
Treatment of HSV-2, HCMV, or HIV.
An antiviral effective, nontoxic dose.
Administration for a period sufficient to mitigate the infection.

Claim 18 does not expressly recite hepatitis B. Hepsera was approved by the FDA for chronic hepatitis B, while the patent’s issued method claim identifies HSV-2, HCMV, and HIV.[2] The chemical claims, rather than claim 18 alone, were therefore the more relevant protection for the marketed active ingredient.

When did US Patent 5,663,159 expire?

The patent issued September 2, 1997. Its relevant priority and filing history placed the ordinary patent term in November 2014. Public patent records generally identify November 2014 as the expiration period for US 5,663,159.[1]

Event	Date or period
Priority and foreign-family activity	1993-1994 period
U.S. application	1990s
Patent issued	September 2, 1997
Standard U.S. patent term endpoint	November 2014
Current enforceability	Expired

The expiration date should be distinguished from FDA regulatory exclusivity. Patent expiration does not itself establish the date of an ANDA approval, because FDA review, Paragraph IV litigation, pediatric exclusivity, and other listed patents can affect market entry.

What was the Orange Book status of adefovir dipivoxil?

Adefovir dipivoxil was approved by the FDA as Hepsera, sponsored by Gilead Sciences, for chronic hepatitis B.[2] The Orange Book historically listed patent information associated with the approved product. US 5,663,159 was the principal early patent associated with the adefovir dipivoxil prodrug estate.[3]

The patent’s Orange Book significance came from its coverage of the drug substance rather than from a narrow tablet formulation. A generic applicant seeking approval for adefovir dipivoxil could face a listed-patent certification issue even if the proposed product used a different excipient system.

FDA exclusivity and patent protection were separate:

Protection type	Relevance
New chemical entity exclusivity	Expired before current generic competition
Drug patent	US 5,663,159 expired in 2014
Method-of-use protection	Limited by the diseases recited in claim 18
Formulation protection	Not the principal subject of this patent
Biosimilar protection	Not applicable to this small molecule

Were there Paragraph IV challenges to Hepsera?

Generic applicants could challenge listed Hepsera patents through an ANDA Paragraph IV certification. A Paragraph IV applicant asserts that a listed patent is invalid, unenforceable, or not infringed.

The commercial consequences were:

A Paragraph IV notice could trigger a Hatch-Waxman patent action.
A timely infringement suit could impose a 30-month FDA approval stay.
The generic applicant could litigate the compound claims, method claims, or both.
Once the relevant patent barriers expired, approval depended primarily on FDA review and product development rather than continued enforcement of US 5,663,159.

The historical record should be separated from current risk. Because US 5,663,159 is expired, it does not presently support a new infringement action against a generic adefovir dipivoxil product. Any current challenge analysis must focus on later patents, regulatory exclusivity, labeling, and product-specific issues rather than the expired patent itself.

What later patents could affect adefovir dipivoxil?

The later estate may include patents directed to:

Pharmaceutical compositions
Tablet formulations
Stability improvements
Manufacturing processes
Specific dosage forms
Alternative salts or crystalline forms
Treatment of hepatitis B
Combination therapy
Packaging or storage systems

These rights must be analyzed separately from US 5,663,159. A patent covering adefovir dipivoxil itself is materially different from a patent covering a particular formulation or a labeled method of use.

For a generic applicant, the key legal question is whether the proposed product practices a valid unexpired claim. A formulation patent may be avoided through a noninfringing excipient system. A method-of-use patent may be addressed through a section viii statement or a carved-out label if the FDA-approved use and patent claim permit that approach.

How strong was the patent estate for adefovir dipivoxil?

At its peak, US 5,663,159 was commercially strong because it combined:

A direct claim to the marketed compound.
Broad genus claims covering related ester prodrugs.
Monoester coverage.
Pharmaceutical composition protection.
A therapeutic-use claim.
Multiple dependent claims providing fallback positions.

The strongest claim was claim 9 because it identifies adefovir dipivoxil with chemical precision. Claims 1 and 2 were broader but more exposed to prior-art and claim-construction issues. Claim 18 was narrower by disease indication and administration route.

The estate’s principal weakness was timing. The patent was filed before the commercial launch of Hepsera but expired after the product had spent only a limited period on the market. Once the compound patent expired, broad chemical protection was no longer available to block ordinary generic versions.

How does adefovir dipivoxil compare with tenofovir products?

Adefovir dipivoxil and tenofovir disoproxil fumarate are related phosphonate prodrugs, but they are not the same compound.

Attribute	Adefovir dipivoxil	Tenofovir disoproxil fumarate
Core antiviral	Adefovir, PMEA	Tenofovir, PMPA
Purine base	Adenine	Adenine
Key structural distinction	2-phosphonylmethoxyethyl side chain	Propyl-linked phosphonate analogue with methyl substitution
Brand	Hepsera	Viread
Primary historical use	Chronic hepatitis B	HIV and chronic hepatitis B
Patent landscape	US 5,663,159 and related rights	Separate tenofovir patent families
Biosimilar pathway	Not applicable	Not applicable

Structural similarity does not create literal infringement. A tenofovir product must be analyzed under the claims of the relevant tenofovir patents, not under US 5,663,159.

What generic launch risks exist?

The expired status of US 5,663,159 removes the principal direct compound-patent barrier. Remaining generic launch risks may include:

Unexpired later formulation patents.
FDA requirements for bioequivalence.
Difficulties reproducing dissolution or stability characteristics.
Limited commercial demand for adefovir relative to newer HBV therapies.
Labeling constraints created by method-of-use patents.
Manufacturing controls for ester hydrolysis and impurity limits.
Supply-chain and active-ingredient availability.
Product liability and pharmacovigilance exposure.

A generic applicant using the same active ingredient and a materially different formulation would generally focus on ANDA bioequivalence, patent certifications, and any remaining listed patents. The expired compound claims would not independently prevent launch.

What licensing deals affected the adefovir program?

Adefovir originated from work associated with Antonín Holý and the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences. Gilead developed the compound and commercialized adefovir dipivoxil under rights connected to that research relationship.[4]

The licensing history is relevant because patent ownership and commercialization rights were not necessarily held by the same entities throughout development. Patent assignment records, collaboration agreements, and product commercialization arrangements should therefore be distinguished from the named assignee on the issued U.S. patent.

Key Takeaways

US 5,663,159 is a core adefovir dipivoxil prodrug patent.
Claim 9 expressly covers adefovir dipivoxil.
Claims 1 and 2 cover broader families of esterified phosphonate antivirals.
Claims 13 and 17 extend coverage to pharmaceutical compositions and monoester compounds.
Claim 18 covers oral treatment of HSV-2, HCMV, or HIV, not hepatitis B expressly.
The patent issued on September 2, 1997 and expired in November 2014 under its ordinary term.
The patent is no longer an enforceable generic-entry barrier.
Adefovir dipivoxil is a small molecule, so biosimilar analysis does not apply.
Current commercial risk depends on later formulation, manufacturing, labeling, and regulatory rights.
Tenofovir patent families must be analyzed separately from the adefovir estate.

FAQs

Is US 5,663,159 still enforceable?

No. The patent reached the end of its ordinary U.S. patent term in November 2014.

Does US 5,663,159 cover Hepsera tablets?

It covers the adefovir dipivoxil active compound and pharmaceutical compositions containing covered compounds. It is not limited to a particular tablet excipient formulation.

Does the patent cover adefovir itself without ester groups?

The patent is directed principally to esterified phosphonate prodrugs and related intermediates. Unesterified adefovir must be evaluated against the exact structural limitations of each asserted claim and against separate foundational PMEA patents.

Can a generic use a different ester than the pivaloyloxymethyl group?

A different ester may still fall within claims 1 or 2 if it satisfies the R4 and R5 limitations. It may avoid claim 9, which specifically identifies the di-pivaloyloxymethyl compound, but not necessarily the broader genus claims.

Is adefovir dipivoxil subject to biosimilar competition?

No. Adefovir dipivoxil is a chemically synthesized small molecule regulated through the generic-drug pathway, principally an ANDA, rather than the biologics biosimilar pathway.

References

United States Patent and Trademark Office. (1997). Antiviral phosphonate derivatives, U.S. Patent No. 5,663,159.
U.S. Food and Drug Administration. (2002). Hepsera (adefovir dipivoxil) prescribing information.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
Gilead Sciences, Inc. (2002). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0481214	⤷ Start Trial	91036	Luxembourg	⤷ Start Trial
European Patent Office	0481214	⤷ Start Trial	300131	Netherlands	⤷ Start Trial
European Patent Office	0481214	⤷ Start Trial	SPC/GB03/030	United Kingdom	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,663,159

Summary for Patent: 5,663,159